CAPR - カプリコ―ル・セラピュ―ティクス (Capricor Therapeutics Inc.) カプリコ―ル・セラピュ―ティクス

 CAPRのチャート


 CAPRの企業情報

symbol CAPR
会社名 Capricor Therapeutics Inc (カプリコ―ル・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ナイル・セラピューティクス(Nile Therapeutics Inc)は開発段階のバイオ医薬品会社であり、心不全を主とする心血管疾患を治療するための製品を開発する。同社は「Cenderitide」と「CU-NP」の2つの薬品候補を開発している。「Cenderitide」は、心不全を治療するキメラ性ナトリウム利尿ペプチドである。「CU-NP」は人体により生成されるアミノ酸チェーンと同一であるアミノ酸チェーン、特にC型ナトリウム利尿ペプチド(CNP)の環構造、及びウロジラチンのN-末端とC-末端で構成される合理的に設計された前臨床ナトリウム利尿ペプチドである。「Cenderitide」はメイヨー・クリニック(Mayo Clinic)の心臓・腎臓研究室の科学者に設計されている。「CU-NP」はメイヨー・クリニックにおける心臓・腎臓研究室の科学者に合理的に設計されたナトリウム利尿ペプチドである。   カプリコ―ル・セラピュ―ティクスは開発段階の米国のバイオ医薬品企業。心臓血管と腎臓疾患治療薬の研究、開発に注力する。心臓疾患治療向け新薬候補にはカ―ディオスフェアから得た同種異系細胞からなるCAP-1002、カ―ディオスフェアから得た自家細胞CAP-1002がある。   Capricor Therapeutics, Inc., is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. We are now developing two potential vaccines for COVID-19 as part of our exosome platform.
本社所在地 8840 Wilshire Blvd. 2nd Floor Beverly Hills CA 90211 USA
代表者氏名 Frank I. Litvack フランク・I・リヴァック
代表者役職名 Independent Executive Chairman of the Board
電話番号 +1 310-358-3200
設立年月日 35217
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 40人
url www.capricor.com
nasdaq_url https://www.nasdaq.com/symbol/capr
adr_tso
EBITDA EBITDA(百万ドル) -13.62626
終値(lastsale) 1.0441
時価総額(marketcap) 32104897.2552
時価総額 時価総額(百万ドル) 20.54025
売上高 売上高(百万ドル) 1.59310
企業価値(EV) 企業価値(EV)(百万ドル) 11.58228
当期純利益 当期純利益(百万ドル) 1.77510
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Capricor Therapeutics Inc revenues decreased 57% to $804K. Net loss increased 9% to $7.8M. Revenues reflect Collaboration income decrease from $1.4M to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.33 to -$0.28.

 CAPRのテクニカル分析


 CAPRのニュース

   Capricor Therapeutics slumps 9% on $75M stock offering  2021/06/21 13:27:49 Seeking Alpha
   Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference #stocks chatter  2021/06/18 18:50:09 Mehabe
Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference - #stocks chatter
   Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference  2021/06/17 13:00:00 Intrado Digital Media
LOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (Capricor or the Company) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, announced today that Capricor CEO, Linda Marbán, Ph.D., will provide an update on recent findings after a preliminary review of the Companys ongoing open-label extension study of the Phase II HOPE-2 trial with lead asset, CAP-1002, at the Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference .
   Hedge Funds Are Betting On Capricor Therapeutics, Inc. (CAPR)  2021/06/13 18:37:29 Insider Monkey
   Capricor Therapeutics to Participate in BIO Digital 2021 Conference  2021/06/10 13:15:00 Intrado Digital Media
LOS ANGELES, June 10, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that the company will participate in 1x1 meetings with investors and potential partners at BIO Digital 2021 being held June 10-11 and June 14-18, 2021.
   Capricor Therapeutics (CAPR) Set to Announce Quarterly Earnings on Thursday  2021/03/05 15:22:47 Transcript Daily
Capricor Therapeutics (NASDAQ:CAPR) will be announcing its earnings results after the market closes on Thursday, March 11th. CAPR traded up $0.02 during trading on Friday, reaching $5.08. 3,000 shares of the stock were exchanged, compared to its average volume of 1,218,792. The stock has a market cap of $103.88 million, a P/E ratio of -4.75 […]
   Exosome Therapeutic Market (COVID-19 Impact Analysis) 2020 to Eyewitness Massive Growth by 2026, Leading Players are Exopharm, AEGLE Therapeutics, Jazz Pharmaceuticals, ReNeuron Group, Capricor Therapeutics  2020/10/27 13:11:57 OpenPR
This Exosome Therapeutic Market research report makes available state-of-the-art information about the entire market along with the holistic view of the market. This global market research report displays a complete overview of the market, including myriad of aspects such as
   The Week Ahead In Biotech: FDA Decisions For Mesoblast And Eton, Coronavirus Vaccine Updates  2020/09/26 18:40:57 Benzinga
Biotech stock reversed course last week, dragged lower by the broader market weakness. The week's news flow was headlined by Johnson & Johnson (NYSE: JNJ ) kickstarting a Phase 3 trial of its coronavirus vaccine candidate. A few clinical readouts released during the week triggered strong moves. Vaccinex Inc (NASDAQ: VCNX ) and AC Immune SA (NASDAQ: ACIU ) were among the worst decliners of the week, with the former reacting to a failed mid-stage trial of lead drug in Huntington's disease, while the latter plunged after an out-licensed Alzheimer's drug flunked a mid-stage trial. Here are the key catalysts for the unfolding week. Conferences World Muscle Society, or WMS, 25: Virtual Congress: Sept. 28-Oct. 2 Annual Northeast Amyotrophic Lateral Sclerosis, or NEALS, meeting: Sept. 30- Oct. 1 Heart Failure Society of America, or HFSA, Virtual Annual Scientific Meeting 2020: Sept. 30-Oct. 6 virtual Jefferies Cell Therapy Summit: Oct. 5-6 Virtual Jefferies Gene Therapy/Editing Summit: Oct. 1-2 North American Neuroendocrine Tumor Society, or NANETS', Multidisciplinary NET Medical Virtual Symposium: Oct.
   Why Capricor Therapeutics Is Trading Higher Today  2020/08/25 15:34:42 Benzinga
Capricor Therapeutics (NASDAQ: CAPR ) shares are trading higher on Tuesday after the company announced the U.S. Food and Drug Administration has accepted its investigational new drug application for a Phase 2 clinical trial of CAP-1002 in patients with COVID-19. The study will enroll patients who have a confirmed diagnosis of … Full story available on Benzinga.com
   Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update  2020/08/06 20:01:00 GlobeNewswire
Exosome Platform for COVID-19-Novel Multivalent Exosome mRNA and VLP Vaccine Candidates Underway in Animal Studies--Preclinical Data Shows Positive…
   The Week Ahead In Biotech: FDA Decisions For Mesoblast And Eton, Coronavirus Vaccine Updates  2020/09/26 18:40:57 Benzinga
Biotech stock reversed course last week, dragged lower by the broader market weakness. The week's news flow was headlined by Johnson & Johnson (NYSE: JNJ ) kickstarting a Phase 3 trial of its coronavirus vaccine candidate. A few clinical readouts released during the week triggered strong moves. Vaccinex Inc (NASDAQ: VCNX ) and AC Immune SA (NASDAQ: ACIU ) were among the worst decliners of the week, with the former reacting to a failed mid-stage trial of lead drug in Huntington's disease, while the latter plunged after an out-licensed Alzheimer's drug flunked a mid-stage trial. Here are the key catalysts for the unfolding week. Conferences World Muscle Society, or WMS, 25: Virtual Congress: Sept. 28-Oct. 2 Annual Northeast Amyotrophic Lateral Sclerosis, or NEALS, meeting: Sept. 30- Oct. 1 Heart Failure Society of America, or HFSA, Virtual Annual Scientific Meeting 2020: Sept. 30-Oct. 6 virtual Jefferies Cell Therapy Summit: Oct. 5-6 Virtual Jefferies Gene Therapy/Editing Summit: Oct. 1-2 North American Neuroendocrine Tumor Society, or NANETS', Multidisciplinary NET Medical Virtual Symposium: Oct.
   Why Capricor Therapeutics Is Trading Higher Today  2020/08/25 15:34:42 Benzinga
Capricor Therapeutics (NASDAQ: CAPR ) shares are trading higher on Tuesday after the company announced the U.S. Food and Drug Administration has accepted its investigational new drug application for a Phase 2 clinical trial of CAP-1002 in patients with COVID-19. The study will enroll patients who have a confirmed diagnosis of … Full story available on Benzinga.com
   Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update  2020/08/06 20:01:00 GlobeNewswire
Exosome Platform for COVID-19-Novel Multivalent Exosome mRNA and VLP Vaccine Candidates Underway in Animal Studies--Preclinical Data Shows Positive…
   Capricor Therapeutics to Present Second Quarter 2020 Financial Results and Recent Corporate Update on August 6  2020/07/30 13:15:00 GlobeNewswire
Company to Host Conference Call and Webcast, August 6, 2020, at 4:30 p.m. ET
   The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More  2020/07/29 11:32:01 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Medpace Holdings Inc (NASDAQ: MEDP ) (saw an extension of its earnings-induced momentum) NeoGenomics, Inc. (NASDAQ: NEO )(reacted to its second-quarter results) OncoSec Medical Inc (NASDAQ: ONCS ) Penumbra Inc (NYSE: PEN ) Qiagen NV (NYSE: QGEN ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Trevena Inc (NASDAQ: TRVN ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 28) Nkarta Inc (NASDAQ: NKTX ) Nurix Therapeutics Inc (NASDAQ: NRIX )(IPOed Friday) Verrica Pharmaceuticals Inc (NASDAQ: VRCA ) Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN ) Stocks In Focus Alector Slips After Presenting Dementia Drug Trial Results Alector Inc (NASDAQ: ALEC ) announced at the virtual 2020 Alzheimer's Association International Conference, or AAIC, preliminary results from a Phase 1b and open-label Phase 2 studies of AL001 for the treatment of people with frontotemporal dementia with a progranulin gene mutation, or FTD-GRN, with the Phase 1 study showing AL001 was generally safe and well-tolerated.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 カプリコ―ル・セラピュ―ティクス CAPR Capricor Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)